Research progress on the PI3K/AKT signaling pathway in gynecological cancer (Review)

被引：258

作者：

Shi, Xiang ^{[1
]}

Wang, Jingjing ^{[1
]}

Lei, Yu ^{[1
]}

Cong, Caofan ^{[1
]}

Tan, Dailin ^{[2
]}

Zhou, Xianrong ^{[1
]}

机构：

[1] Qianjiang Cent Hosp, Dept Pathol, 22 Zhang Hua St, Qianjiang 433100, Hubei, Peoples R China

[2] Qianjiang Cent Hosp, Dept Clin Lab, Qianjiang 433100, Hubei, Peoples R China

来源：

MOLECULAR MEDICINE REPORTS | 2019年 / 19卷 / 06期

关键词：

gynecological cancer; phosphatidylinositol; 3-kinase; protein kinase B; mechanistic target of rapamycin kinase; THERAPEUTIC TARGET; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL; 3-KINASE; ENDOMETRIAL CARCINOMA; HUMAN-PAPILLOMAVIRUS; EPITHELIAL OVARIAN; MAMMALIAN TARGET; PI3K-AKT PATHWAY; PTEN EXPRESSION; CELL CARCINOMA;

D O I：

10.3892/mmr.2019.10121

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

The phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway is involved in the regulation of multiple cellular physiological processes by activating downstream corresponding effector molecules, which serve an important role in the cell cycle, growth and proliferation. This is a common phenomenon; overactivation of the pathway is present in human malignancies and has been implicated in cancer progression, hence one of the important approaches to the treatment of tumors is rational drug design using molecular targets in the PI3K/AKT signaling pathway. In brief, the present review analyzed the effects of the PI3K/AKT signaling pathway on certain gynecological cancer types.

引用

页码：4529 / 4535

页数：7

共 93 条

[1]

Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B alpha [J].

Alessi, DR ;

James, SR ;

Downes, CP ;

Holmes, AB ;

Gaffney, PRJ ;

Reese, CB ;

Cohen, P .

CURRENT BIOLOGY, 1997, 7 (04) :261-269

[2]

AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth [J].

Altomare, DA ;

Wang, HQ ;

Skele, KL ;

De Rienzo, A ;

Klein-Szanto, AJ ;

Godwin, AK ;

Testa, JR .

ONCOGENE, 2004, 23 (34) :5853-5857

[3]

Role of translocation in the activation and function of protein kinase B [J].

Andjelkovic, M ;

Alessi, DR ;

Meier, R ;

Fernandez, A ;

Lamb, NJC ;

Frech, M ;

Cron, P ;

Cohen, P ;

Lucocq, JM ;

Hemmings, BA .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (50) :31515-31524

[4]

Vascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancer [J].

Andorfer, Peter ;

Heuwieser, Alexander ;

Heinzel, Andreas ;

Lukas, Arno ;

Mayer, Bernd ;

Perco, Paul .

BMC SYSTEMS BIOLOGY, 2016, 10

[5]

PDGF-DEPENDENT TYROSINE PHOSPHORYLATION STIMULATES PRODUCTION OF NOVEL POLYPHOSPHOINOSITIDES IN INTACT-CELLS [J].

AUGER, KR ;

SERUNIAN, LA ;

SOLTOFF, SP ;

LIBBY, P ;

CANTLEY, LC .

CELL, 1989, 57 (01) :167-175

[6]

Cancer-specific mutations in PIK3CA are oncogenic in vivo [J].

Bader, AG ;

Kang, SY ;

Vogt, PK .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (05) :1475-1479

[7]

The Molecular Biology of Endometrial Cancers and the Implications for Pathogenesis, Classification, and Targeted Therapies [J].

Bansal, Nisha ;

Yendluri, Vimala ;

Wenham, Robert M. .

CANCER CONTROL, 2009, 16 (01) :8-13

[8]

Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer [J].

Barra, Fabio ;

Evangelisti, Giulio ;

Desideri, Lorenzo Ferro ;

Di Domenico, Stefano ;

Ferraioli, Domenico ;

Vellone, Valerio Gaetano ;

De Cian, Franco ;

Ferrero, Simone .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (02) :131-142

[9]

Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study [J].

Behbakht, Kian ;

Sill, Michael W. ;

Darcy, Kathleen M. ;

Rubin, Stephen C. ;

Mannel, Robert S. ;

Waggoner, Steven ;

Schilder, Russell J. ;

Cai, Kathy Q. ;

Godwin, Andrew K. ;

Alpaugh, R. Katherine .

GYNECOLOGIC ONCOLOGY, 2011, 123 (01) :19-26

[10]

Integrated genomic analyses of ovarian carcinoma [J].

Bell, D. ;

Berchuck, A. ;

Birrer, M. ;

Chien, J. ;

Cramer, D. W. ;

Dao, F. ;

Dhir, R. ;

DiSaia, P. ;

Gabra, H. ;

Glenn, P. ;

Godwin, A. K. ;

Gross, J. ;

Hartmann, L. ;

Huang, M. ;

Huntsman, D. G. ;

Iacocca, M. ;

Imielinski, M. ;

Kalloger, S. ;

Karlan, B. Y. ;

Levine, D. A. ;

Mills, G. B. ;

Morrison, C. ;

Mutch, D. ;

Olvera, N. ;

Orsulic, S. ;

Park, K. ;

Petrelli, N. ;

Rabeno, B. ;

Rader, J. S. ;

Sikic, B. I. ;

Smith-McCune, K. ;

Sood, A. K. ;

Bowtell, D. ;

Penny, R. ;

Testa, J. R. ;

Chang, K. ;

Dinh, H. H. ;

Drummond, J. A. ;

Fowler, G. ;

Gunaratne, P. ;

Hawes, A. C. ;

Kovar, C. L. ;

Lewis, L. R. ;

Morgan, M. B. ;

Newsham, I. F. ;

Santibanez, J. ;

Reid, J. G. ;

Trevino, L. R. ;

Wu, Y. -Q. ;

Wang, M. .

NATURE, 2011, 474 (7353) :609-615

← 1 2 3 4 5 6 7 8 9 10 →